Witzens-Harig, M., Memmer, M. L., Dreyling, M., & Hess, G. (2013). A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial. BioMed Central.
Citação norma ChicagoWitzens-Harig, Mathias, Marie Luise Memmer, Martin Dreyling, and Georg Hess. A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients With Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma – the STORM Trial. BioMed Central, 2013.
Citação norma MLAWitzens-Harig, Mathias, Marie Luise Memmer, Martin Dreyling, and Georg Hess. A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients With Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma – the STORM Trial. BioMed Central, 2013.